On April 5, 2024 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), reported that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media (Press release, Heidelberg Pharma, APR 5, 2024, View Source [SID1234641813]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The R&D webinar will feature presentations from Heidelberg Pharma’s management team, alongside leading Key Opinion Leaders (KOLs) in the ADC field, Rakesh Dixit, PhD, CEO of Bionavigen, Gaithersburg, USA, and Jonathan Kaufman, MD, Associate Professor of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, USA.
The event will provide information on Heidelberg Pharma’s lead clinical ATAC product candidate HDP-101 targeting relapsed and refractory multiple myeloma as well as its proprietary ADC toolbox and therapeutic product pipeline. A clinical presentation of first efficacy data from the Phase I/IIa clinical trial with HDP-101 will take place at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, San Diego, California from 5 to 10 April 2024.
Attendees will have the opportunity to participate in a live Q&A session at the end of the presentation or submit questions in advance of the event.
For further information on the R&D webinar, or to register your interest, please contact Optimum Strategic Communications at [email protected] or register using the link below:
A live recording of the R&D webinar will be accessible via the press & investor section of the Company website shortly after the event or on View Source